Thetis Pharmaceuticals Receives $1.9 Million Fast-Track NIH Grant to Advance Novel Inflammatory Bowel Disease Drug Pipeline Toward Clinical Investigation BRANFORD, Conn., May 23, 2018 (GLOBE NEWSWIRE) -- Thetis Pharmaceuticals, a biopharmaceutical company developing novel therapies for treatment of inflammatory bowel disease (IBD), today announced...

FDA & Industry Veteran Brian E. Harvey, MD, PhD, Joins Thetis Pharmaceuticals as Senior Medical Director BRANFORD, Conn., May 07, 2018 (GLOBE NEWSWIRE) -- Thetis Pharmaceuticals LLC (“Thetis”), a biopharmaceutical company developing first-in-class, immuno-resolving small molecule drugs to treat...

Thetis Builds Scientific Advisory Board to Guide Development of Immuno-Resolving Therapies for IBD BRANFORD, Conn., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Thetis Pharmaceuticals LLC (“Thetis”), a biopharmaceutical company developing oral, “immuno-resolving” therapies to treat inflammatory bowel...

Thetis Pharmaceuticals Awarded $2.3 Million Fast-Track NIH Grant to Develop Immuno-Resolving Therapy for Inflammatory Bowel Disease BRANFORD, Conn., Nov. 16, 2017 (GLOBE NEWSWIRE) -- Thetis Pharmaceuticals, a biopharmaceutical company developing “immuno-resolving” therapies for treatment of inflammatory bowel disease (IBD),...